



Kiadis Pharma receives two orphan drug designations for Reviroc™ from the FDA

Amsterdam, December 8, 2008 – Biopharmaceutical company Kiadis Pharma announces today that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc™ Orphan Drug Designations (ODD) for the treatment of two types of Non-Hodgkin Lymphoma (NHL). One ODD has been granted for diffuse large B-cell lymphoma and the other one for the treatment of follicular lymphoma. Reviroc™ is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.

"This is an important strategic milestone in the development of Reviroc™ and we are very pleased with the orphan drug designations received from the FDA", says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.

The FDA's orphan drug designation is reserved for new therapies being developed to treat diseases or conditions that affect fewer than 200,000 people in the United States. The orphan drug designation provides for an accelerated review process, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the US after product approval.

About Reviroc™

Reviroc™ is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as a graft. Bone marrow transplants are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. One of the limitations of autologous bone marrow transplantations is the high relapse rate associated with this treatment. This is often caused by the presence of cancer cells in the transplant. Reviroc™ has been developed to remove tumor cells from the graft.

About Kiadis Pharma

Kiadis Pharma is an oncology focused biopharmaceutical development company with cell based products in clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures performed in blood cancer patients. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit www.kiadis.com.

For more information please contact:

Kiadis Pharma B.V.
Eefje Simpelaar
Director Communications
Email: e.simpelaar@kiadis.com
Tel: +31 20 3140250
Mob +31 6 10829344